A rapid-ACCE review of CYP2C9 and VKORC1 alleles testing to inform warfarin dosing in adults at elevated risk for thrombotic events to avoid serious bleeding.
about
Fulfilling the promise of personalized medicine? Systematic review and field synopsis of pharmacogenetic studiesInfluence of CYP2C9 and VKORC1 on patient response to warfarin: a systematic review and meta-analysisEffect of genetic variants, especially CYP2C9 and VKORC1, on the pharmacology of warfarinIntegration of genetic, clinical, and INR data to refine warfarin dosing.Evaluation of the PharmGKB knowledge base as a resource for efficiently assessing the clinical validity and utility of pharmacogenetic assays.Testing of VKORC1 and CYP2C9 alleles to guide warfarin dosing. Test category: pharmacogenomic (treatment).Validation and comparison of pharmacogenetics-based warfarin dosing algorithms for application of pharmacogenetic testingComparison of commercial genetic-testing services in Korea with 23andMe service.Genotype and risk of major bleeding during warfarin treatment.Race influences warfarin dose changes associated with genetic factors.A Novel Admixture-Based Pharmacogenetic Approach to Refine Warfarin Dosing in Caribbean Hispanics.Predicting warfarin dosage in European-Americans and African-Americans using DNA samples linked to an electronic health record.Correlation between single nucleotide polymorphisms in CYP4F2 and warfarin dosing in Chinese valve replacement patients.Prioritizing genomic applications for action by level of evidence: a horizon-scanning method.Pharmacogenetic testing of CYP2C9 and VKORC1 alleles for warfarin.Kidney function influences warfarin responsiveness and hemorrhagic complications.Genetic testing before anticoagulation? A systematic review of pharmacogenetic dosing of warfarinThe Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Initiative: methods of the EGAPP Working Group.A regulatory science perspective on warfarin therapy: a pharmacogenetic opportunity.Warfarin sensitivity genotyping: a review of the literature and summary of patient experience.Pharmacogenetics of vitamin K antagonists: useful or hype?Frequency of VKORC1 (C1173T) and CYP2C9 genetic polymorphisms in Egyptians and their influence on warfarin maintenance dose: proposal for a new dosing regimen.Adherence and variability in warfarin dose requirements: assessment in a prospective cohort.Genetic determinants of variability in warfarin response after the dose-titration phase.Are predictive biomarkers of toxicity worth having? An economic model.NAVAGATE: a rubric to move from pharmacogenomics science to pharmacogenomics practice.How is genetic testing evaluated? A systematic review of the literature.Prediction of optimal warfarin maintenance dose using advanced artificial neural networks.VKORC1, CYP2C9 and CYP4F2 genetic-based algorithm for warfarin dosing: an Italian retrospective study.
P2860
Q21091172-D9945A95-4D9D-4B21-8060-FC60C0B49FF1Q27002899-65BB0F11-14E0-4929-A206-692552320A20Q28276514-6B47250B-B51E-4E2E-8EC1-1C11A8A9FF3DQ33550741-4A3FA6E7-9A5D-4A5C-BFCF-0B995BC88F34Q33626802-BA352703-B146-43D7-98FC-D6170DFFFBEFQ33704981-1D8360AE-5DFC-40D7-A21D-EE05AC85BBC3Q33813830-AE138691-F066-460A-8FBA-66D24BAFAF09Q33892611-586201D9-AF8C-43DD-AF5A-0DFEFA86D43CQ35006973-D48CDBF7-E385-412C-96F3-5DB96E8AC615Q35884265-94D37B42-92FD-45F7-953D-05BA053C4774Q35888757-9C60B238-5A81-43FE-B0B3-1F2176FAFE45Q35991881-28F9EB7B-FD19-40B2-ABBD-6EFF0670E361Q36368040-EA8277B2-7FA4-4A3B-AE97-6D52743197F8Q36398661-80C5F17D-8B2E-448D-9E37-A29E6468A124Q37087348-293E758A-81DC-42B0-BA41-853C988E7D99Q37146449-663B676B-87A0-425F-AAB3-B7ADAC69D9E9Q37160420-AEB55C45-5847-4847-A32C-43EBDD92F15EQ37277889-30A65FFC-A1FC-4B16-85D8-9D60F408B727Q37380399-C3F437AE-A844-49AE-9377-1F353861BA0CQ37454438-B0FD61FF-9A82-4EB0-A0E8-EC6D5C10F722Q37461474-492C3002-64E5-4921-814B-3AAE5C1B3420Q38984342-98741502-DA4A-4BDD-9B9A-1510DE7E2522Q39483670-F7FA3790-0E6A-4C61-AFE6-1ACE43BBA8EEQ43113299-1982C156-3C1F-4E27-87BF-3A6F32980E53Q43922399-6D8FDF43-F250-4230-B538-27D34D094BE6Q44357874-118FF69B-C4A1-4F9B-86E6-2ABAE6EADEB7Q50106856-FEE0C924-F0CF-4C9E-90BE-BAA10668AD7DQ51134013-FEBE165B-42AC-4845-9FDB-83DC42998678Q51622508-E878201F-CC74-4758-B93A-317C3EB7B860
P2860
A rapid-ACCE review of CYP2C9 and VKORC1 alleles testing to inform warfarin dosing in adults at elevated risk for thrombotic events to avoid serious bleeding.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on February 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
A rapid-ACCE review of CYP2C9 ...... nts to avoid serious bleeding.
@en
A rapid-ACCE review of CYP2C9 ...... nts to avoid serious bleeding.
@nl
type
label
A rapid-ACCE review of CYP2C9 ...... nts to avoid serious bleeding.
@en
A rapid-ACCE review of CYP2C9 ...... nts to avoid serious bleeding.
@nl
prefLabel
A rapid-ACCE review of CYP2C9 ...... nts to avoid serious bleeding.
@en
A rapid-ACCE review of CYP2C9 ...... nts to avoid serious bleeding.
@nl
P2093
P2860
P1433
P1476
A rapid-ACCE review of CYP2C9 ...... nts to avoid serious bleeding.
@en
P2093
Glenn E Palomaki
James E Haddow
Margaret Piper
Monica R McClain
P2860
P2888
P356
10.1097/GIM.0B013E31815BF924
P407
P577
2008-02-01T00:00:00Z